Endocrinology. Increasing the daily dose of recombinant follicle stimulating hormone (Puregon ® ) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation

By Out Henk J.  

Human Reproduction, Vol. 15, Iss. 1, 2000-01 ,pp. : 29-35

Oxford University Press

Access to resources Recommend Favorite

Endocrinology. A prospective, randomized comparison of ovulation induction using highly purified follicle-stimulating hormone alone and with recombinant human luteinizing hormone in in-vitro fertilization

By Sills E.Scott  

Human Reproduction, Vol. 14, Iss. 9, 1999-09 ,pp. : 2230-2235

Oxford University Press

Access to resources Recommend Favorite

Endocrinology. Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone (Puregon ® ) by Pen-injector and syringe

By Voortman G.  

Human Reproduction, Vol. 14, Iss. 7, 1999-07 ,pp. : 1698-1702

Oxford University Press

Access to resources Recommend Favorite

The impact of insulin resistance on the outcome of ovulation induction with low-dose follicle stimulating hormone in women with polycystic ovary syndrome

By Dale PO  

Human Reproduction, Vol. 13, Iss. 3, 1998-03 ,pp. : 567-570

Oxford University Press

Access to resources Recommend Favorite

Endocrinology: Sequential step-up and step-down dose regimen: an alternative method for ovulation induction with follicle-stimulating hormone in polycystic ovarian syndrome

By Hugues Jean-Noël   Cédrin-Durnerin Isabelle   Avril Catherine   Bulwa Sylvie   Hervé Florence   Uzan Michéle  

Human Reproduction, Vol. 11, Iss. 12, 1996-12 ,pp. : 2581-2584

Oxford University Press

Access to resources Recommend Favorite